ALSO READUSFDA gives final nod for Aurobindo's Meropenem anti-bacterial injection Aurobindo Pharma dips on USFDA procedural observations on Hyderabad unit Lupin, Aurobindo Pharma hit fresh 52-week lows Aurobindo Pharma gets USFDA nod to make attention deficit disorder drug US regulator's inspections at Aurobindo spook investors
Sevelamer Carbonate oral suspension, a therapeutic equivalent generic version of Genzyme’s Renvela oral suspension. The product is being launched immediately, Aurobindo Pharma said in a statement.
Sevelamer Carbonate oral suspension is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis, it added.
According to IMS, the approved product has an estimated market size of US$ 140 million for the twelve months ending April 2017.
This is the 116th ANDA (including 19 tentative approvals) to be approved out of Unit VII formulation facility in Hyderabad used for manufacturing oral products.
Aurobindo now has a total of 323 ANDA approvals (288 Final approvals including 16 from Aurolife Pharma LLC and 35 tentative approvals) from USFDA.